Ambrx Biopharma Net Income 2020-2022 | AMAM
Ambrx Biopharma net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
| Ambrx Biopharma Annual Net Income (Millions of US $) |
|
|---|---|
| 2021 | $-68 |
| 2020 | $-17 |
| 2019 | $-20 |
| Ambrx Biopharma Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2022-06-30 | |
| 2021-12-31 | $-68 |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.071B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $154.721B | 9.45 |
| GSK (GSK) | United Kingdom | $71.915B | 9.49 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.215B | 19.14 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.249B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.615B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.532B | 23.00 |
| Biohaven (BHVN) | United States | $1.307B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.726B | 5.71 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.376B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.067B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.023B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.022B | 0.00 |
